Exchange: NASDAQ·Updated 02:51 PM EST
BMEA logo

BMEA Biomea Fusion Inc

$0.5197
$0.0317
(6.50%)
Today
Reported EarningsNov 10
Mkt Cap$35.47M
Vol646,179.00

About BMEA

Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic disorders, such as diabetes. It offers its lead product candidate, BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The company was founded by Thomas Butler and Ramses Erdtmann in August 2017 and is headquartered in San Carlos, CA.
52

Neutral Sentiment

How do you feel about BMEA?

knowhope_
$BMEA as a long holder, right now, I feel dumb for staying. But in few more months I know I’ll feel extra dumb for not staying. Now let’s have a green day
17
knowhope_
$BMEA Have faith my friends. The molecules are good. This market is huge. The results are coming and then the cash. Patience is key.
26
Blackone83
$BMEA 🚨 $BMEA — Potential surprise at ObesityWeek 2026! Biomea Fusion’s official BMF-650 abstract explicitly states that patients in cohorts C1–C4 received six weeks of daily treatment, with weight-loss results to be reported at both 4 and 6 weeks. Yet the October 13 readout focused on Day 29: * C3 (300 mg): −3.2% * C4 (400 mg): −2.1% * Pooled placebo: −0.1% Importantly, C3 was still losing weight rapidly in week 4, with approximately 1.47 kg lost during that week alone. If that momentum continued, a 5–6% weight loss at week 6 is mathematically plausible, although this remains an extrapolation, not a reported result. Combined with promising GI tolerability and rapid titration, strong week-6 data could significantly strengthen BMF-650’s clinical profile. 🔥 Could the November 16 poster reveal meaningful data missing from the October readout? The key will be actual Day 42 results, placebo-adjusted efficacy and tolerability. #BMEA #BiomeaFusion #BMF650 #ObesityWeek
19
asa123
$BMEA Dear Biomea, here’s what you do: You reprice the 14M October warrants from $2.50 to $0.50. The offer is valid for one week, with no strings attached, provided holders surrender their original warrants upon exercise. I presume all you need to do is 2 phone calls: CVI and Blue Owl. You collect $7M—roughly another quarter of operating cash—more than enough to monetize 650 and 211/212 without the pressure of imminent financing. Then you let the 23M June warrants expire worthless on December 20 and enter 2027 with no warrant overhang and a much cleaner cap table, ready for a pharma deal.
1
10
Creisi
$BMEA On October 19, BMEA made a job posting for a TMF Specialist. 6 month contract. For those who don't know, a TMF Specialist is instrumental in an asset sale, as they help prepare and transfer clinical documentation to a buyer, allowing the buyer to assess trial integrity, regulatory compliance, and the quality of the drug's clinical evidence. They ensure all clinical trial documentation at BMEA is complete, accurate, organized, compliant, and readily accessible for external review. The fact BMEA made this a 6 month contract suggests the company is planning an asset sale, partnership or exit within 6 months. Although this suggests this is happening, and is what executives are planning; there are many things which can alter those plans. Yes, this is a clear indication that an asset sale or corporate sale is being worked on behind the scenes. As I explained and posted evidence of previously. Licensing, partnering and M&A in general, typically takes several months.
19
MeninWatcher999
$BMEA a new analyst price target has come in over the last few days. Interesting by who, piper sandler... $4
19
hashbridges
$BMEA yeah. This whole things is now getting valued at about 2X their cash on hand ($20-24M) for multi-billion dollar drug candidates (3 of them) that have passed every test so far. I continue to be mind blown.
1
16
septrading
$BMEA, say what you will; desperation would have been taking poor financing back in September and/or running the ATM. Zero dilution instead. Their actions appear quite far from desperate. So, unless you want to believe they are asleep at the wheel (yeah, that Cohort 5 placebo fluke didn't help), they are clearly working on better alternatives.
18
ap20
$BMEA I haven’t been in the “wait to the warrants expire” camp before you do a deal.. The warrant holders obviously had the company’s best interest as a consideration when they participated in the offering and I don’t mind them being rewarded. My napkin math on a $1B buyout would zing us $10 with options exercised or $13.75 without. Either beats $.56.. Best to all.
14
Raika26
$BMEA The presentation is tomorrow, before the market opens; let’s hope for some good news or a rumor.
9
septrading
$BMEA My bullish thesis is that BMF-500 could bring Biomea its first deal, and the strongest evidence for it may still be unpublished. The EHA report covered only 27 of the 35 patients enrolled. If one or more of the original patients who had failed gilteritinib experienced prolonged survival, and some of the final eight also achieved durable remissions, a prospective partner could see considerably more value in BMF-500 than investors can see today. The September timing is what gives that possibility weight for me. Nearly five months after the trial ended, Biomea submitted its completion update on the very day it launched an equity offering, then pulled the offering before the market opened the next morning. I suspect the prospect of an oncology deal made management more willing to walk away from dilution. A late-breaking ASH oral could be the first public sign. My expectation is that Biomea would prefer to price a deal after the 23 million December warrants expire, then use the upfront cash to advance icovamenib and return to BMF-650 with its six-week outpatient weight-loss data and a stronger negotiating position.
11
Creisi
$BMEA Just so everyone understands what Icovamenib brings to the table. If the Q1 2027 trial delivers any result over a 0.9% reduction, then it's projected annual sales volume would exceed $20 billion per year. A massive blockbuster! Icovamenib is not just another drug; it is a disease modifying short therapy blockbuster in the most lucrative sector in pharmaceuticals, diabetes. So, this is why BMEA executives would prefer keeping it away from any predatory big Pharma suitors. It is also the reason why Big Pharma want it included in a deal. The fight behind closed doors is BMEA executives doing everything they can to hold it in order to realize its multi-billion dollar value.
17
Creisi
$BMEA So I'm told BMF-500 was completely scrubbed from the external website as of this morning. I would say this structural website change suggests a 70% chance BMF-500 is sold to an external BP player. In the biopharma sector, pulling an asset down from a website is almost never a random operational task. It is a deliberate action that carries clear legal implications. There's still about a 30% chance it was strictly a website cleansing, but the argument it's simply a website cleansing is kinda weak. The fact it occurred today, potentially the day before their quarterly earnings is interesting. BP buyer would definitely require BMF-500 to be scrubbed from the website in the manner it has just been done. So that elevates the hypothesis that the drug is sold. If it was sold, expect an announcement with the Corporate Report. I would look for an SEC filing within 1 to 2 days; potentially, tomorrow morning.
17
Eternal_Optimist
$BMEA morning! Bought 10k shares at 0.546. Got my average share price to 0.99! Thank you everyone that sold to help me increase my ownership of this wonderful company (with its own unique issues of course). I am long and strong and like I said earlier, get your big boy/girl pants on folks! Trading basically at cash as mentioned this morning. ZERO dollar value attached to all three drugs combined…. Shorts exhausted (like my thumbs on the old Nintendo controllers!)…. This setup is how every Mother Of All Short Squeezed has happened! Fear not longs, we are in this together. Once more unto the breach my friends! It’s our obligation to fight back the short and bearish hordes!
17
MeninWatcher999
$BMEA just to let people know. Biomea Fusion has posted two new job roles this last 5 days. Tomorrow is Earnings, earnings are Due pre market.
1
14
Eternal_Optimist
$BMEA Just bought 6750 shares at 0.6885. Got my average down to 1.18 and am taking advantage of these prices to increase my ownership of the company! Bears/shorts fully in control of the stock and board but thats ok! I fully believe in the pipeline of THREE DRUGS THAT WORK! The leadership is experienced and i am hopeful execution will improve. We will see a bottom soon i believe. Was busy working away in the hospital the last few days and just caught up with a very bearish board! Longs, keep the faith! I posted this morning as a BUY is real talk and not random noise!
17
AI_Bull_
$BMEA WOW! Very tempting to buy at 0.45 or below. If price gets there. A potential lucrative long term 2027 opportunity right here in the market. I will watch the price very carefully.
9
septrading
$BMEA Hitchcock understands how to develop important medicines and work with sophisticated pharmaceutical partners. His understanding of development portfolios, combinations, and collaboration inside a major drug company is substantial. Let's get it done!
16
Danzzzzzzzz
$BMEA I suspect the latest short interest is now between 18 and 20M shares, which is about 25% of the total available shares. That's huge. Look at the latest short share availability: zero! There have been no shares available to short since October 22nd. Any PR, and it's a short squeeze. Last but not least, remember to disable share lending with your broker
1
13
Eternal_Optimist
$BMEA Just got back from my Hawaii trip. Bought 10K shares this morning at 0.4975. Thanks! Lowered cost by 5 cents! Let’s go!
10

Advertisement|Remove ads.